Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context

Eur J Heart Fail. 2017 Nov;19(11):1551-1553. doi: 10.1002/ejhf.919. Epub 2017 Aug 28.

Authors

Lucia S D'Angiolella^{1

2}, Paolo A Cortesi^{1

2}, Claudia Pitotti³, Daniela Ritrovato³, Lorenzo G Mantovani¹, Michele Senni⁴

Affiliations

¹ Research Centre on Public Health (CESP), University of Milan Bicocca, Monza, Italy.
² Fondazione Charta, Milan, Italy.
³ Novartis Farma SpA, Origgio, Italy.
⁴ Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy.

PMID: 28849615
DOI: 10.1002/ejhf.919

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Aminobutyrates / therapeutic use*
Angiotensin Receptor Antagonists / therapeutic use
Biphenyl Compounds
Drug Combinations
Female
Heart Failure / drug therapy*
Heart Failure / epidemiology
Heart Failure / physiopathology
Humans
Italy / epidemiology
Male
Middle Aged
Morbidity / trends
Stroke Volume / physiology*
Survival Rate / trends
Tetrazoles / therapeutic use*
Treatment Outcome
Valsartan

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Tetrazoles
Valsartan
sacubitril and valsartan sodium hydrate drug combination